Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target

Pacira BioSciences is viewed positively because Viatris’s all-cash $36.50/share acquisition implies about a 45% premium and values the company at roughly $1.65 billion, or about 9.3x LTM adjusted EBITDA, which validates the franchise’s commercial and strategic worth. The business contributes two high-margin marketed assets, EXPAREL with about $587 million of LTM revenue and ZILRETTA with about $121 million, plus a ~340-person specialty commercial team that aligns well with Viatris’s meloxicam opportunity and international reach. Additional upside comes from PCRX-201, where Phase 2A topline data is expected late 2026, while more than $50 million of annual run-rate cost synergies supports the deal economics and limits downside.

Pacira BioSciences is under pressure because its valuation depends heavily on a transaction that could fail if the >50% tender condition is not met, HSR clearance stalls, or a material adverse change emerges, any of which could send shares back toward pre-announcement levels. Beyond deal risk, the business remains concentrated in Exparel, which has been on the market for 14 years and faces ANDA and other competitive threats, while the NOPAIN Act may not be renewed at the end of 2027, creating reimbursement risk. Although ZILRETTA, iovera, and PCRX-201 provide diversification, PCRX-201 remains early-stage and the company still faces commercial, regulatory, liquidity, and macro pressure that limits confidence in durable standalone fundamentals.